3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
5
Phase 3
3
Phase 4
2
Phase EARLY_PHASE1
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Gastrointestinal
1
Dermatologic
1
Conditions
Liver Neoplasms
1
Interventions
Oxaliplatin
780
Fluorouracil
638
Capecitabine
575
Gemcitabine
478
Leucovorin
459
Bevacizumab
445
Irinotecan
444
Cisplatin
338
Radiotherapy
283
Cetuximab
252
Paclitaxel
180
S 1 (combination)
176
pembrolizumab
173
Docetaxel
156
Drug Therapy
147
Nivolumab
146
sintilimab
143
tislelizumab
131
apatinib
131
130-nm albumin-bound paclitaxel
128
Folfox protocol
121
durvalumab
119
Albumin-Bound Paclitaxel
117
camrelizumab
107
lenvatinib
106
Panitumumab
106
regorafenib
102
Surgical Procedures, Operative
102
Sorafenib
99
Radiation
88
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Polyethylene Glycols
×
Gastrointestinal
×
Clear all
NCT02006030
2018-09-04
TACE
Polaris Group
Phase 2
Completed
30 enrolled